Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listMirtazapine

Mirtazapine

Synonym(s):1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine

  • CAS NO.:85650-52-8
  • Empirical Formula: C17H19N3
  • Molecular Weight: 265.35
  • MDL number: MFCD00865427
  • EINECS: 288-060-6
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-19 15:53:33
Mirtazapine Structural

What is Mirtazapine?

Absorption

The absorption of this drug is rapid and complete. Due to first pass metabolism in the liver and metabolism in the gut wall, absolute bioavailability is about 50%. Peak blood concentrations are attained within about 2 hours after an oral dose. Food has little effect on the absorption of mirtazapine, and no dose adjustment is required if it is taken with food. Steady-state levels are achieved by about 5 days after the initial dose. Mirtazapine pharmacokinetics vary across gender and age range. Females and the elderly population have been shown to have higher blood concentrations in comparison to males and younger adults.

Toxicity

LD50
Oral LD50 was 830 mg/kg in male Swiss mice 24 hours after being administered mirtazapine.
Overdose information
Activated charcoal should be administered during an overdose to absorb excess mirtazapine. General supportive therapy should be employed, including maintenance of an adequate airway, oxygen therapy, and ventilation therapy. Vital signs and cardiac rhythm must be monitored. It is not advisable to induce vomiting. Gastric lavage with a large-bore orogastric tube with proper protection of the airway is recommended . There is no antidote for mirtazapine available currently. Consider the possibility of mirtazapine combined with other drugs in an overdose and ensure to contact the local poison control center for guidance on management.
Carcinogenesis
At higher than normal doses, mirtazapine increased the incidence of hepatocellular adenomas and carcinomas in male mice. The highest doses administered to the mice were about 20 and 12 times the maximum recommended human dose (MRHD). Hepatocellular tumors and thyroid follicular adenoma/cystadenomas in male rats occurred at an increased rate at a higher mirtazapine dose (60 mg/kg/day). In female rats, both the medium (20 mg/kg/day) and higher (60 mg/kg/day) doses of mirtazapine increased the rate of hepatocellular adenomas. The relevance of these findings in humans is not known at this time.
Impairment of Fertility
Mirtazapine was administered to rats at doses reaching 100 mg/kg (equivalent to 20 times the maximum recommended human dose) in a fertility study. There was no impact on mating and conception, however, there was a disturbance of reproductive (estrous) cycling at higher doses. These doses were measured to be at least 3 times the maximum recommended human dose. Loss of fetus before implantation in the uterus occurred when doses equivalent to 20 times the maximum recommended dose were administered.
Use in pregnancy
This drug is categorized as a pregnancy category C drug. No adequate studies in pregnant women have been conducted. In rats, an increased rate of post-implantation demise occurred with mirtazapine administration. Additionally, an increase in deaths of rat pups during the first 3 days of lactation with a decrease in pup birth weight was noted. Studies on animals are not always relevant to human response. Mirtazapine should be used during pregnancy only if the clinical need outweighs the possible risks to the fetus.
Use in nursing
Whether this drug is excreted in human milk is unknown. Many drugs are found excreted in human breast milk, therefore caution is advised if this drug is used during nursing.

Chemical properties

White Solid

The Uses of Mirtazapine

Mirtazapine (Remeron, Avanza) is a potent tetracyclic antidepressant. Mirtazapine (Remeron, Avanza) used primarily in the treatment of depression. It is also sometimes used as a hypnotic, antiemetic, and appetite stimulant, and for the treatment of anxiet

The Uses of Mirtazapine

Mirtazapine is an α2-Adrenergic blocker; analogue of Mianserin. Antidepressant.

Indications

This drug is indicated for the treatment of major depressive disorder and its associated symptoms.
Mirtazapine has been used off-label for a variety of conditions including panic disorder, generalized anxiety disorder, dysthymia, tension headaches, hot flushes, post-traumatic stress disorder (PTSD), sleep disorders, substance abuse disorders, and sexual disorders, among others.

Background

Mirtazapine is a tetracyclic piperazino-azepine antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder. The effects of this drug may be observed as early as 1 week after beginning therapy.
In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery.

What are the applications of Application

Mirtazapine is a potent SR-2, SR-3, and Histamine H1 receptor antagonist

Definition

ChEBI: Mirtazapine is a benzazepine and a tetracyclic antidepressant. It has a role as an alpha-adrenergic antagonist, a serotonergic antagonist, a histamine antagonist, an anxiolytic drug, a H1-receptor antagonist and a oneirogen.

brand name

Remeron (Organon).

General Description

Mirtazapine is a tetracyclic antidepressant marketed under the trade names Remeron?, Avanza, or Zispin for treatment of depression.?This Certified Spiking Solution? is suitable for LC/MS or GC/MS applications in forensic analysis, clinical toxicology, or urine drug testing.

Biological Activity

Antidepressant agent; potent 5-HT 2 , 5-HT 3 and histamine H 1 receptor antagonist and moderately potent α 2 -adrenoceptor antagonist (pK i values are 8.05, ~ 8.1, 9.3 and 6.95 respectively). Enhances noradrenalin (NA) release in rat brain via inhibition of α 2 -adrenergic autoreceptors and displays only weak affinity for monoamine transporters (pK i values are 5.6, < 5 and < 5.1 for inhibition of NA, dopamine and 5-HT uptake respectively). Increases hippocampal NA and 5-HT levels in rats following systemic administration in vivo .

Biochem/physiol Actions

Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). Mirtazapine agonizes selective adrenergic and serotonergic receptors so that both NE release and 5-HT1A mediated serotonergic signaling are increased.

Pharmacokinetics

General effects and a note on suicidality
Mirtazapine is effective in treating moderate to severe depression and treats many symptoms normally associated with this condition. These symptoms may include disturbed sleep, lack of appetite, and anhedonia, in addition to anxiety.. It is important to note that suicidal ideation and behavior may emerge or increase during treatment with mirtazapine, as with any other antidepressant. This risk is especially pronounced in younger individuals. Patients, medical professionals, and families should monitor for suicidal thoughts, worsening depression, anxiety, agitation, sleep changes, irritable behavior, aggression, impulsivity, restlessness, and other unusual behavior when this drug is taken or the dose is adjusted. Do not administer mirtazapine to children. When deciding to prescribe this drug, carefully consider the increased risk of suicidal thoughts and behavior, especially in young adults.
Effects on appetite and weight gain
In addition to the above effects, mirtazapine exerts stimulating effects on appetite, and has been used for increasing appetite and decreasing nausea in cancer patients. Some studies and case reports have shown that this drug improves eating habits and weight gain in patients suffering from anorexia nervosa when administered in conjunction with psychotherapy and/or other psychotropic drugs. In a clinical trial, women with depression experienced a clinically significant mean increase in body weight, fat mass, and concentrations of leptin when treated with mirtazapine for a 6-week period, with a lack of effect on glucose homeostasis.
Effects on sleep
The use of mirtazapine to treat disordered sleep has been leveraged from its tendency to cause somnolence, which is a frequently experienced adverse effect by patients taking this drug. Mirtazapine has been shown to exert beneficial effects on sleep latency, duration, and quality due to its sedating properties. Insomnia is a common occurrence in patients with depression, and mirtazapine has been found to be efficacious in treating this condition.

Clinical Use

Antidepressant

Veterinary Drugs and Treatments

Currently, the only FDA approved indication for mirtazapine is depression in humans. Reported veterinary uses include treatment of chemotherapy-induced nausea and vomiting (CINV); anorexia associated with renal failure (azotemia), congestive heart failure, gastro-intestinal disorders, liver disease, or neoplasia. Other uses suggested include stress induced diseases; insomnia; post-pyometra symptoms; and post-operative inappetance. Studies have shown that mirtazapine also alleviated sleep apnea in rats and humans.
There are case reports published in human literature of mirtazapine use as treatment for non-mechanical vomiting after gastric bypass, CINV, obsessive-compulsive disorder, nocioception and chronic pain, migraine headache prophylaxis, anti-psychotic induced akathisia, idiopathic nausea and vomiting, serotonin syndrome induced nausea, anorexia, irritable bowel syndrome, resistant hyperemesis gravidarum, and for the treatment of negative symptoms of schizophrenia. Studies in rats have also shown that mirtazapine significantly improves memory.

Drug interactions

Potentially hazardous interactions with other drugs
Alcohol: increased sedative effect.
Antidepressants: possibly increased risk of serotonergic effects with fluoxetine, fluvoxamine or venlafaxine; CNS excitation and hypertension with MAOI and moclobemide - avoid.
Antimalarials: avoid with artemether and lumefantrine and piperaquine with artenimol.
Methylthioninium: risk of CNS toxicity - avoid if possible.

Metabolism

Mirtazapine is heavily metabolized in humans. Demethylation and hydroxylation and subsequent glucuronide conjugation are the major pathways by which mirtazapine is metabolized. Data from in vitro studies on human liver microsomes show that cytochrome 2D6 and 1A2 lead to the formation of the 8-hydroxy metabolite of mirtazapine. The CYP3A enzyme metabolizes this drug into its N-desmethyl and N-oxide metabolites. There are various other unconjugated metabolites of this drug that are pharmacologically active, but are measured in the blood at limited concentrations.

Metabolism

Extensively metabolised in the liver via CYP2D6, CYP1A2, and CYP3A4. The major biotransformation pathways are demethylation and oxidation followed by glucuronide conjugation. The N-desmethyl metabolite is pharmacologically active. Elimination is via urine and faeces (15%).

storage

Store at RT

Properties of Mirtazapine

Melting point: 114-116°C
Boiling point: 432.4±45.0 °C(Predicted)
Density  1.22±0.1 g/cm3(Predicted)
Flash point: 9°C
storage temp.  2-8°C
solubility  DMSO: ~8 mg/mL, soluble
form  solid
pka 8.10±0.20(Predicted)
color  white
CAS DataBase Reference 85650-52-8(CAS DataBase Reference)

Safety information for Mirtazapine

Signal word Warning
Pictogram(s)
ghs
Exclamation Mark
Irritant
GHS07
GHS Hazard Statements H302:Acute toxicity,oral
H336:Specific target organ toxicity,single exposure; Narcotic effects
Precautionary Statement Codes P261:Avoid breathing dust/fume/gas/mist/vapours/spray.
P264:Wash hands thoroughly after handling.
P264:Wash skin thouroughly after handling.
P270:Do not eat, drink or smoke when using this product.
P271:Use only outdoors or in a well-ventilated area.
P301+P312:IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

Computed Descriptors for Mirtazapine

Abamectin manufacturer

NEULAND LABS

1Y
Phone:+914067611600
product: Mirtazapine 98%
Inquiry

Aurobindo Pharma Limited

1Y
Phone:+91-4066725000
product: Mirtazapine 61337-67-5 / 85650-52-8 98%
Inquiry

Sun Pharmaceutical Industries Ltd

1Y
Phone:+912243244324
product: 61337-67-5 / 85650-52-8 Mirtazapine 98%
Inquiry

Adeep Life Sciences Pvt Ltd

1Y
Phone:+91-9515114455
Whatsapp: +91-9515114455
product: Mirtazapine 98%
Inquiry

HRV Global Life Sciences

1Y
Phone:+91-9820219686
Whatsapp: +91 9820219686
product: Mirtazapine 99%
Inquiry

Megafine Pharma

1Y
Phone:+91-9867686666
Whatsapp: +91 9867686666
product: Mirtazapine 61337-67-5 / 85650-52-8 99%
Inquiry

Basil Drugs AND Pharmaceuticals Pvt Ltd

1Y
Phone:+91-9619320820
Whatsapp: +91 9619320820
product: 61337-67-5 / 85650-52-8 Mirtazapine 98%
Inquiry

Almon Industries

1Y
Phone:+91-9898908297
Whatsapp: +91-9898908297
product: 61337-67-5 / 85650-52-8 98%
Inquiry

Ralington Pharma

1Y
Phone:+91-9687771722
Whatsapp: +91- 9687771722
product: Mirtazapine 98%
Inquiry

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.